The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study

What Was Tested

The paper reports a study of Semaglutide in the context of pcos, published as an observational study.

The researchers explored changes in body weight, cardiometabolic and endocrine parameters in obese women with PCOS who continued treatment with metformin 2 years after discontinuation of short-term intervention with semaglutide.

Why It Was Studied

There are some studies implying that metformin might attenuate weight regain.

The weight trajectory after discontinuation of short-term semaglutide treatment in obese women with PCOS who continued metformin treatment has not yet been evaluated.

Who Took Part

The study group was 25 women.

PubMed indexes the participants as adults, women only.

How the Study Was Run

At week 16, semaglutide was discontinued.

Weight change, cardiometabolic, and endocrine parameters were assessed 2 years after semaglutide discontinuation.

What Was Measured

The weight trajectory after discontinuation of short-term semaglutide treatment in obese women with PCOS who continued metformin treatment has not yet been evaluated.

PubMed files the paper under topics including Metformin, Glucagon-Like Peptides, Polycystic Ovary Syndrome, Weight Loss, Obesity, Hypoglycemic Agents and Semaglutide.

Author keywords: PCOS, maintenance and weight regain.

What This Means in Plain Language

This is an observational study of Semaglutide in 25 women in people with pcos.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Semaglutide compound page, PCOS research.